Richard L. Wasserman MD PhD

PubMed

• 1 citations
  Patient-Reported Outcomes on Food Immunotherapy Differ Between Countries and Foods: Results From COFAITH.
  Pablo Rodríguez Del Río, Carmen Riggioni, Antoine Deschildre, Matthew Greenhawt, Sabine Schnadt
  The Journal of Allergy and Clinical Immunology. in Practice. 2025-08-01
• 1 citations
  10 ways to improve your management of food allergy.
  Aikaterini Anagnostou, Jay Lieberman, Theresa Bingemann, Tim Buckey, Antonella Cianferoni
  Annals of Allergy, Asthma & Immunology. 2025-05-01
• 1 citations
  Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunode...
  Niraj C Patel, Jolan E Walter, Richard L Wasserman, Arye Rubinstein, Suthida Kankirawatana
  Journal of Clinical Immunology. 2025-03-14

Journal Articles

• Intravenous Gammaglobulin Prophylaxis for Newborn Infants.  
  Wasserman RL, Pediatr. Inf. Dis. 5:620-621
• Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.  
  Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, Wasserman RL, Baggish JS, Saunders R, Grimbacher B, Clin Exp Immunology. 2012: 169:172-181
• Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.  
  Craig TJ, Bewtra AK, Hurewitz D, Levy R, Janss G, Jacobson KW, Packer F, Bernstein JA, Rojavin MA, Machnig T, Keinecke OH, Wasserman RL, Asthma and Allergy Proc. 33:354-61
• Novel Method of Subcutaneous Immunoglobulin Administration Facilitated by Recombinant Human Hyaluronidase: A Phase Three Clinical Study of Efficacy, Tolerability and P...  
  Wasserman RL, Melamed I, Stein MR, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI and the IGSC, 10% with rHuPH20 Study Group, J. Allergy Clin Immunol. 2012. 130:951-57
• C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies.  
  Schneider L, Hurewitz D, Wasserman R, Obtulowicz K, Machnig T, Moldovan D, Reshef A, Craig TJ, Pediatr Allergy Immunol. 2013 Feb;24(1):54-60. doi: 10.1111/pai.12024
• Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks.  
  Prematta M, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, Craig T, Adv Ther, 1-10. DOI 10.1007/s12325-0053-5
• C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life.  
  Bewtra AK, Levy RJ, Jacobson KW, Wasserman RL, Machnig T, Craig TJ, Allergy and Asthma Proc. 33:427-431
• Transfusion-associated cytomegalovirus infection and acquired immune deficiency syndrome in an infant.  
  Shannon K, Ball E, Wasserman RL, Murphy FK, Luby J, Buchanan GR, J. Pediatr. 103:859-863
• Ataxia -Telangectasia associated with sarcoidosis.  
  Fleck RM, Meyers LK, RL Wasserman, Tigelaar RE, Freeman RG, Pediatr. Derm. 3:339-343
• HIV infection detected by the PCR in an agammaglobulinemic patient.  
  Young KKY, Peter JB, Wasserman RL, AIDS 4:468-469
• Cephaloskeletal dysplasia (Tabyi-Linder syndrome; osteodysplastic primordial dwarfism type III): report of two cases and a review of the literature.  
  Vichi GF, Currarino G, Wasserman RL, Duvina PL, Filippi L, Pediatr Radiol 30:644-652
• Office-based oral immunotherapy for food allergy is safe and effective.  
  Wasserman RL, Sugerman RW, Mireku-Akomeah N, Mansfield L, Baker JW, J Allergy Clin Immunol. 2011 Jan;127(1):290-1; author reply 291-2
• Neonatal Sepsis: The Potential of Granulocyte Transfusion.  
  Wasserman RL, Hospital Practice 17:95-104
• Monoclonal Antibodies: Progress and Promise.  
  Polin RA, Wasserman RL, Lab. Manage. 21:33-38,40,43,44
• Unconventional therapies for neonatal sepsis.  
  Wasserman RL, Pediatr. Inf. Dis. 2:421-423
• Caustic Substance Injuries.  
  Wasserman RL, Ginsburg C, J. Pediatr. 107:169-174
• Safety of L-proline as a stabilizer for immunoglobulin products.  
  Hagan JB, Wasserman RL, Baggish J, Spycher M, Berger M, Shashi V, Lohrmann E, Sullivan K, Expert Rev Clin Immunol 8(2) 169-187
• Perinatally acquired AIDS.  
  Wasserman RL, Dallas Med. J. 73:292-295
• Perinatal Aids.  
  Wasserman RL, 1993 AJCEN 1993/5 Review Issue: 40-47
• IgG subclass determinations.  
  Wasserman RL, Pediatr. Inf. Dis. 7:303
• Antibody deficiency - ubiquitous problem or useless concept?  
  Wasserman RL, Eur J Pediatr (1988) 147:458-459
• Immunodeficiency that is not AIDS - Primary Immunodeficiency Disease.  
  Wasserman RL, Dallas Medical Journal
• Evaluating humoral immunity: The role of immunization with bacterial polysaccharide vaccine.  
  Wasserman RL, Sorensen RU, Pedia Inf Dis J. 1999, 18(2):157-163
• Pediatric Asthma Management in the 21st Century.  
  Wasserman RL, Texas Pharm. 2002, 122(4) 22-24,35
• Advances in the Treatment of Pediatric Asthma. Infectious Disease in Children.  
  Brunell, PA, Irani, MA, Kattan, M, Martinez, FD, Shapiro, G, Wasserman, RL, CME supplement
• Join now to see all

Books/Book Chapters

• Pharmacokinetics of a new 10% Intravenous Immunoglobulin. 
  Chapter: Pharmacokinetics of a new 10% Intravenous Immunoglobulin 
  Page 272 - 278Wasserman RL, Church JA, Peter HH, et.alEur J Pharm Sci 37, 28
• Structure and evolution of immunoglobulin heavy chain variable regions. 
  Page 3 - 18Capra JD, Wasserman RL, Querinjean P, Kehoe JMFEBS Proceedings, Budapest
• The Glycoconjugates. 
  Chapter: Immunoglobulins 
  Wasserman RL, Capra JDEditors: MI Horowitz, W Pigman.Academic Press, New York
• Biological Basis of Immunodeficiency. 
  Chapter: Primary structural conservation in the evolution of IgM 
  Page 169 - 176McCumber LJ, Wasserman RL, Capra JDEditors: EW Gelfand, HM Dosch.Raven Press, New York
• Immunohematology. 
  Chapter: Monoclonal Antibodies: Production and Use 
  Wasserman RLEditors: E. Steane.American Dade, Miami
• Current therapy in pediatric infectious disease. 
  Chapter: Chronic granulomatous disease 
  Page 275 - 279Wasserman RLEditors: JD Nelson.B.C. Decker Inc, Toronto
• Current therapy in pediatric infectious disease. 
  Chapter: Antibody deficiency states 
  Page 271 - 275Wasserman RLEditors: JD Nelson.B.C. Decker Inc., Toronto
• Human disease: Autoimmunity and human heavy chain variable regions. 
  Chapter: Polymorphism’s of immunologically relevant loci 
  Page 378 - 382Sanz I, RL Wasserman, Hwang LY, Hasemann C, Thomas J, Tucker P, Capra JDEditors: F. Morriss.Quality Medical Publishing Inc., St. Louis
• Essentials Pediatric Intensive Care. 
  Chapter: Immunologic Disorders 
  Page 172 - 174Wasserman RLEditors: D Levin and F Morriss.Quality Medical Publishing, Inc., St. Louis
• 1001 Healthy Baby Answers. 
  Chapter: Asthma 
  Page 93 - 98Wasserman RLEditors: GC Morchower.Sourcebooks, Inc, Naperville, IL
• 1001 Healthy Baby Answers. 
  Chapter: Food Allergy 
  Page 262 - 267Wasserman RLSourcebooks, Inc, Naperville, IL
• Join now to see all

Abstracts/Posters

• Subcutaneous Immunoglobulin Replacement Therapy for Primary Immunodeficiency: High-Dose versus Low-Dose Treatment using Hizentra.
  Hagan J, Wasserman RL, Zenker O, Borte M, AAAAI 2011 International Conference
• Rapid Clearance of L-Proline After Intravenous and Subcutaneous Infusion With L-Proline–Stabilized Immunoglobulin Replacement Products.
  Hagan JB, Robak T, Church JA, Rojavin M, Wasserman RL, Clinical Immunology Society Annual Meeting 2011
• Clinical Immunology Society Tolerability of Human Immunoglobulin 10% (IgG) Administered Subcutaneously (SC) or Facilitated With Recombinant Human Hyaluronidase (rHuPH2...
  Melamed I, Wasserman RL, Stein M, Rubinstein A, McCoy B, Engl W, Leibl H, Gelmont D, Schiff RI and the rHuPH20-facilitated IGSC Study Group, Clinical Immunology Society Annual Meeting 2011
• Local Tolerability of Subcutaneous Infusions With 20% Immunoglobulin: Results From a Phase 3 Study in Subjects With Primary Immunodeficiency.
  Spector S, Wasserman RL, Melamed I, Rojavin MA, Hagan JB, Clinical Immunology Society Annual Meeting 2011
• Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (...
  Schiff RI, Wasserman RL, Melamed I, Stein M, Engl W, Leibl H,Gelmont D, AAAAI 2011 International Conference
• Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency ...
  Rubinstein A, Wasserman RL, Melamed I, Stein M, McCoy B, Engl W, Leibl H,Gelmont D, Schiff RI, AAAAI 2011 International Conference
• Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (...
  Schiff RI, Wasserman RL, Melamed I, Stein M, Engl W, Leibl H,Gelmont D, AAAAI 2011 International Conference
• Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficienc...
  Leibl H, Wasserman RL, Melamed I, Stein M, Engl W,Schiff RI, Gelmont D, Grossman WJ, AAAAI 2011 International Conference
• New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD).
  Grossman WJ, Wasserman RL, Melamed I, Stein M, Leibl H, Schiff RI, Gelmont D, AAAAI 2011 International Conference
• Efficacy And Pharmacokinetics Of A New 10% Liquid Intravenous Immunoglobulin (Bivigam™ Ivig) In Patients With Primary Immunodeficiency.
  Wasserman RL, Church J, Strausbaugh S, Schroeder, Ballow M, Harris J, Melamed I, Elkayam D, Lumry W, Suez D, Rehman S. Safety, Clinical Immunology Society Annual Meeting 2011
• Peanut Oral Immunotherapy (OIT) of Food Allergy (FA) Carries a Significant Risk of Eosinophilic Esophagitis (EoE).
  Wasserman RL, Sugerman RW, Mireku-Akomeah N, Gallucci AR, Pence DM, Long NA, AAAAI 2011 International Conference
• Oral Immunotherapy (OIT) of Food Allergy (FA) Successfully Desensitizes Most Patients.
  Gallucci AR, Wasserman RL, Sugerman RW, Mireku-Akomeah N, Pence DM, Long NA, AAAAI 2011 International Conference
• Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Patients with Primary Imm...
  Gelmont D, Wasserman RL, Melamed I, Stein M, Rubinstein A, McCoy B, Engl W, Leibl H, Schiff RI, Grossman WJ, AAAAI 2011 International Conference
• Office Based Oral Desensitization of Patients With Non-Anaphylactic Sensitivity to Foods Is Safe and Effective.
  Gallucci AR, Wasserman RL, Mansfield LE, Hutteman HR, Ruvalcaba AM, Long NA, Pence DM, AAAAI 2010 International Conference
• Office Based Oral Desensitization of Patients With Anaphylactic Sensitivity to Foods Is Safe and Effective.
  Wasserman RL, Mansfield LE, Gallucci AR, Hutteman HR, Ruvalcaba AM, Long NA, Pence DM, AAAAI 2010 International Conference
• A prospective study (I.M.P.A.C.T.2) of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema.
  TJ Craig, Wasserman TL, Levy RJ, Bewtra AK, Schneider L, Packer F, Yang W, Keinecke HO, Kiessling PC, EAACI Annual Meeting, 2010
• IGIV 10%, Infused Intravenously and Subcutaneously to Subjects with Primary Immunodeficiency Diseases – Efficacy, Tolerability and Pharmacokinetic Comparison.
  Leibl H,Wasserman RL,Stein M, Melamed I, Schiff RI and the IGIV SC study group, First North American Primary Immune Deficiency Conference, 2010
• Normalized Hearing and Improved Speech Discrimination Following Cochlear Implant in an ADA-SCID Patient.
  Wasserman RL and Peters BR, Clinical Immunology Society Annual Meeting 2012
• Characterization of the Effects of Proteolysis and Reduction on Cashew Allergens.
  Mattison CP, Grimm CC, Desormeaux WA, Wasserman RL, AAAAI International Conference 2013
• Long-Term Efficacy and Tolerability of 20% SCIG in the Treatment of Patients With Primary Immunodeficiency Disease.
  Borte M, Wasserman RL, Rojavin MA, Bexon M, Jolles S, AAAAI International Conference 2013
• Long-Term Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Human Immune Globulin G, 10%, and Recombinant Human Hyaluronidase: Phase 3 Extension Stud...
  Melamed I, Wasserman RL, Stein M, Rubinstein A, Puck J, Gupta S, Engl W, Leibl H, Gelmont D, Schiff RI and the IGSC, 10% rHuPH20 Study Group, ACAAI International Conference 2012
• Long-Term Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Human Immunoglobulin G, 10%, and Recombinant Human Hyaluronidase (IGHy): Phase 3 Extensio...
  Melamed I, Wasserman RL, Stein M, Rubinstein A, Puck J, Gupta S, Engl W, Leibl H, Gelmont D, Schiff RI and the IGSC, 10% rHuPH20 Study Group, European Society for Immunodeficiency Conference 2012
• Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Human Immunoglobulin G, 10%, and Recombinant Human Hyaluronidase (IGHy): Subset of Study Patients Wit...
  Wasserman RL, Melamed I, Stein M, Puck J, Gupta S, Engl W, Leibl H, Gelmont D, Schiff RI, and the IGSC, 10% rHuPH20 Study Group, European Society for Immunodeficiency Conference 2012
• Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Human Immunoglobulin G, 10%, and Recombinant Human Hyaluronidase (IGHy) in Patients With Primary Immu...
  Stein M, Wasserman RL, Melamed I, Rubinstein A, Puck J, Gupta S, Engl W, Leibl H, McCoy B, Gelmont D, Schiff I, and the rHuPH20-facilitated IGSC Study Group, European Society for Immunodeficiency Conference 2012
• Pharmacokinetics of Human Immunoglobulin G, 10%, Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously With Recombinant Human Hyaluron...
  Stein M, Wasserman RL, Melamed I, Puck J, Gupta S, Engl W, Leibl H, Gelmont D, Schiff RI and the IGSC, 10% rHuPH20 Study Group, European Society for Immunodeficiency Conference 2012
• Join now to see all

Other

• Common Infusion-Related Reactions to Subcutaneous Immunoglobulin Therapy: Managing Patient Expectations. 
  Wasserman RL, Patient Preference and Adherence. 2008:2
  http://www.dovepress.com//common-infusion-related-reactions-to-subcutaneous-immunoglobulin-thera-pee